2021
Modeling the Cost-Effectiveness of Express Multisite Gonorrhea Screening Among Men Who Have Sex With Men in the United States
Earnest R, Rönn MM, Bellerose M, Menon-Johansson AS, Berruti AA, Chesson HW, Gift TL, Hsu KK, Testa C, Zhu L, Malyuta Y, Menzies NA, Salomon JA. Modeling the Cost-Effectiveness of Express Multisite Gonorrhea Screening Among Men Who Have Sex With Men in the United States. Sexually Transmitted Diseases 2021, 48: 805-812. PMID: 33993161, PMCID: PMC8505150, DOI: 10.1097/olq.0000000000001467.Peer-Reviewed Original ResearchConceptsGonococcal infectionAsymptomatic MSMAnatomic sitesUS MSMIncremental cost-effectiveness ratioMore anatomic sitesCost-effectiveness ratioExtragenital screeningGonorrhea ScreeningPhysical examinationSmall cost savingsAsymptomatic screeningProvider consultationRoutine screeningMore infectionsOnward transmissionVisit costsCumulative health effectsIntervention yearInfectionMSMHealth effectsDiagnostic costsCost-effective optionMen
2020
Population-level Benefits of Extragenital Gonorrhea Screening Among Men Who Have Sex With Men: An Exploratory Modeling Analysis.
Earnest R, Rönn M, Bellerose M, Gift T, Berruti A, Hsu K, Testa C, Zhu L, Malyuta Y, Menzies N, Salomon J. Population-level Benefits of Extragenital Gonorrhea Screening Among Men Who Have Sex With Men: An Exploratory Modeling Analysis. Sexually Transmitted Diseases 2020, 47: 484-490. PMID: 32355108, PMCID: PMC7903327, DOI: 10.1097/olq.0000000000001189.Peer-Reviewed Original ResearchConceptsExtragenital screeningMultisite infectionExtragenital sitesRectal screeningSite-specific prevalenceGonorrhea ScreeningPharyngeal sitesGonorrhea infectionExtragenital infectionsGonorrhea prevalencePopulation-level benefitsRectal sitesImproved screeningDisease controlInfectionPrevalenceIncidenceMenHigh rateSexScreeningRace groupsScreening levelsGonorrheaClinic